Article and Video CATEGORIES
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?
Image
Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.
Get more information about the FLAURA Trial and TIGER-1 Trial.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Article
Da click aquí para más información y para registrarte ahora
Image
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Advance directives are a powerful way to take control of healthcare choices.
These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated.
Forum Discussions
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on
colon cancer and HIV
By Hopish hope on